NRX Pharmaceuticals Files 2024 10-K
Ticker: NRXPW · Form: 10-K · Filed: Mar 14, 2025 · CIK: 1719406
| Field | Detail |
|---|---|
| Company | Nrx Pharmaceuticals, INC. (NRXPW) |
| Form Type | 10-K |
| Filed Date | Mar 14, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, financials, authorized-shares
TL;DR
NRXP 10-K filed: $50M common stock, $12M preferred stock authorized. Full financials out.
AI Summary
NRX Pharmaceuticals, Inc. filed its 2024 10-K on March 14, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly Big Rock Partners Acquisition Corp., is focused on pharmaceutical preparations. Key financial figures include $50,000,000 in authorized common stock and $12,000,000 in authorized preferred stock. The filing also details various share counts and financial metrics relevant to its operations.
Why It Matters
This filing provides investors and stakeholders with a comprehensive overview of NRX Pharmaceuticals' financial health and operational status for the fiscal year 2024, including authorized share capital.
Risk Assessment
Risk Level: medium — The company's financial disclosures, including authorized share capital, are critical for assessing its financial stability and future funding potential.
Key Numbers
- $50,000,000 — Authorized Common Stock (Represents the maximum number of common shares the company can issue.)
- $12,000,000 — Authorized Preferred Stock (Represents the maximum number of preferred shares the company can issue.)
- 2024-12-31 — Fiscal Year End (The period covered by the financial statements in the 10-K.)
- 2025-03-14 — Filing Date (The date the 10-K was submitted to the SEC.)
- 14,591,505 — Common Shares Outstanding (Indicates the total number of common shares currently held by investors.)
Key Players & Entities
- NRX Pharmaceuticals, Inc. (company) — Filer of the 10-K
- Big Rock Partners Acquisition Corp. (company) — Former name of NRX Pharmaceuticals, Inc.
- 2024-12-31 (date) — Fiscal year end
- 2025-03-14 (date) — Filing date
- $50,000,000 (dollar_amount) — Authorized common stock
- $12,000,000 (dollar_amount) — Authorized preferred stock
FAQ
What is the total number of common shares authorized by NRX Pharmaceuticals, Inc. as of December 31, 2024?
As of December 31, 2024, NRX Pharmaceuticals, Inc. had $50,000,000 in authorized common stock.
What was the company's fiscal year end for this 10-K filing?
The fiscal year end for this 10-K filing was December 31, 2024.
When was this 10-K filing submitted to the SEC?
This 10-K filing was submitted to the SEC on March 14, 2025.
What was the former name of NRX Pharmaceuticals, Inc.?
The former name of NRX Pharmaceuticals, Inc. was Big Rock Partners Acquisition Corp.
How many common shares were outstanding as of December 31, 2024?
As of December 31, 2024, there were 14,591,505 common shares outstanding.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 14, 2025 regarding NRX Pharmaceuticals, Inc. (NRXPW).